Join to View Full Profile
7200 Cambridge St9th floor Suite 9AHouston, TX 77030
Phone+1 713-798-2273
Dr. Mandel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jacob Mandel is a neurologist in Houston, TX and is affiliated with Baylor St. Luke's Medical Center. He received his medical degree from Rush Medical College and has been in practice 9 years. He specializes in neurooncology and is experienced in neuro-oncology.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014
Ohio State University HospitalResidency, Neurology, 2009 - 2012- Ohio State University HospitalInternship, Internal Medicine, 2008 - 2009
Rush Medical College of Rush University Medical CenterClass of 2008
Certifications & Licensure
TX State Medical License 2014 - 2027
OH State Medical License 2008 - 2014
American Board of Psychiatry and Neurology Neurology
UCNSNeuro-Oncology
Publications & Presentations
PubMed
- Towards fair decentralized benchmarking of healthcare AI algorithms with the Federated Tumor Segmentation (FeTS) challenge.Maximilian Zenk, Ujjwal Baid, Sarthak Pati, Akis Linardos, Brandon Edwards
Nature Communications. 2025-07-08 - 2 citationsLow-grade glial/glioneuronal tumor with YAP1::FAM118B fusion: A novel molecular finding.Fouad El-Dana, Kenneth Aldape, Zied Abdullaev, Sameer Anil Sheth, Jacob Mandel
Journal of Neuropathology and Experimental Neurology. 2025-04-01 - Discontiguous recurrences of IDH-wildtype glioblastoma share a common origin with the initial tumor and are frequently hypermutated.Malcolm F McDonald, Sricharan Gopakumar, Tareq A Juratli, Ilker Y Eyüpoglu, Ganesh Rao
Acta Neuropathologica Communications. 2025-01-16
Press Mentions
CASSINI Trial Assesses Rivaroxaban for Thromboprophylaxis in Cancer PatientsMarch 13th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
